Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

17.00
-0.5400-3.08%
Post-market: 16.92-0.0845-0.50%19:58 EDT
Volume:4.22M
Turnover:72.00M
Market Cap:13.56B
PE:-15.21
High:17.62
Open:17.30
Low:16.80
Close:17.54
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.56
T/O Rate:2.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:21.53
PE(LYR):-11.77

Loading ...

U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs

Reuters
·
Yesterday

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Reuters
·
Sep 09

U.S. Stocks on the MOVE-Meta, Chime Financial, ServiceTitan

Reuters
·
Sep 09

Jefferies Upgrades Summit Therapeutics to "buy", Shares Up

Reuters
·
Sep 09

Summit Therapeutics Inc. : Jefferies Raises to Buy from Hold; Raises Target Price to $25 from $15

THOMSON REUTERS
·
Sep 09

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Royalty Pharma (RPRX) and Summit Therapeutics (SMMT)

TIPRANKS
·
Sep 08

Shimamura Co Ltd - Notice Concerning Acquisition of Business

Reuters
·
Sep 07

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Dow Jones
·
Sep 04

Summit Therapeutics Stock (SMMT) Rallies on Positive Clinical Trial Results

TIPRANKS
·
Sep 03

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in Pd-L1-Positive Advanced Nsclc in Harmoni-2 Study Conducted by Akeso in China

THOMSON REUTERS
·
Sep 03

Summit Therapeutics Inc Stock (SMMT) Moved Up by 8.95% on Aug 26: Drivers Behind the Movement

TradingKey
·
Aug 26

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

MT Newswires Live
·
Aug 26

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release

MT Newswires Live
·
Aug 26

Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints

MT Newswires Live
·
Aug 26

Summit: Akeso reports ‘positive’ results from Phase III HARMONi-GI11 study

TIPRANKS
·
Aug 26

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

THOMSON REUTERS
·
Aug 26

Summit Therapeutics - Study Meets Key Secondary Endpoints of Pfs and Orr

THOMSON REUTERS
·
Aug 26

Summit Says FDA Sets Nov. 14, 2026 Action Date for Ivonescimab Lung Cancer Filing

Reuters
·
Aug 25

Summit Therapeutics falls -8.5%

TIPRANKS
·
Aug 17

EV targets set to be watered down

cityam
·
Aug 14